

Title (en)  
TREATMENT OF HIV-1 INFECTION AND INFLAMMATORY DISEASE USING CYCLOPHILIN RECEPTOR ANTAGONISTS

Title (de)  
BEHANDLUNG VON HIV-1 INFEKTIONEN UND ENTZÜNDUNGSKRANKHEITEN MIT CYCLOPHILIN-REZEPTOR-ANTAGONISTEN

Title (fr)  
TRAITEMENT DE L'INFECTION PAR VIH-1 ET DE MALADIES INFLAMMATOIRES AU MOYEN D'ANTAGONISTES DU RECEPTEUR DE LA CYCLOPHILINE

Publication  
**EP 1309346 A4 20050601 (EN)**

Application  
**EP 01962087 A 20010810**

Priority  

- US 0125178 W 20010810
- US 63703300 A 20000810

Abstract (en)  

[origin: WO0213763A2] Examples and embodiments of the present invention teach and disclose, inter alia, that the previously known extracellular matrix metalloproteinase inducer protein (EMMPRIN), also known as CD147, is a signal-transducing cellular receptor for cyclophilin (CyP). Accordingly, there is disclosed methods for the treatment of HIV-infection, AIDS, AIDS-related disorders., rheumatoid arthritis (RA), connective tissue disorders, cancer or any condition characterized by local or systemic CyP release, synthesis or binding using the CyP/EMMPRIN interaction as a novel therapeutic intervention target. There is further disclosed pharmaceutical compositions including, anti-EMMPRIN antibodies, and soluble EMMPRIN proteins and peptides that act by inhibiting the CyP/EMMPRIN interaction. The present invention further provides screening assays for the identification of compounds that inhibit the CyP/EMMPRIN interaction.

IPC 1-7  
**A61K 39/395; C07K 16/28; C07K 14/705; C12N 9/90**

IPC 8 full level  
**G01N 33/50** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/06** (2006.01); **C07K 7/00** (2006.01); **C07K 14/47** (2006.01); **C07K 16/18** (2006.01); **C07K 16/46** (2006.01); **C07K 19/00** (2006.01); **C12N 9/64** (2006.01); **C12N 15/48** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/37** (2006.01); **C12Q 1/48** (2006.01); **C12Q 1/66** (2006.01); **G01N 33/15** (2006.01); **G01N 33/53** (2006.01); **G01N 33/566** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)  
**A61P 19/02** (2017.12); **A61P 29/00** (2017.12); **A61P 31/18** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/06** (2017.12); **C12N 9/6491** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)  

- [X] US 5840305 A 19981124 - BUKRINSKY MICHAEL [US], et al
- [A] WO 9945031 A2 19990910 - ABGENIX INC [US], et al
- [PX] PUSHKARSKY TATIANA ET AL: "CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 11, 22 May 2001 (2001-05-22), pages 6360 - 6365, XP002310597, ISSN: 0027-8424
- [X] SHERRY BARBARA ET AL: "Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 4, 17 February 1998 (1998-02-17), pages 1758 - 1763, XP002310598, ISSN: 0027-8424
- [A] KIRSCH A H ET AL: "The pattern of expression of CD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6.", TISSUE ANTIGENS. AUG 1997, vol. 50, no. 2, August 1997 (1997-08-01), pages 147 - 152, XP009041532, ISSN: 0001-2815
- See references of WO 0213763A2

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0213763 A2 20020221; WO 0213763 A3 20020815;** AU 8329501 A 20020225; CA 2418303 A1 20020221; EP 1309346 A2 20030514; EP 1309346 A4 20050601; IL 154358 A0 20030917; JP 2004505997 A 20040226

DOCDB simple family (application)  
**US 0125178 W 20010810;** AU 8329501 A 20010810; CA 2418303 A 20010810; EP 01962087 A 20010810; IL 15435801 A 20010810; JP 2002518911 A 20010810